9.00am - 6.00pm EST | 6.00am - 3.00pm PST

9:00 am Registration & Coffee

9:20 am Chair’s Opening Remark

  • Jeffrey Pollard Director, Professor of Resilience Biology, Medical Research Council Centre for Reproductive Health, University of Edinburgh

Advancing Development of Next Generation Cancer Immunotherapy by Optimizing Clinical Development of CD47/SIRPα Targeted Macrophage Therapies

9:30 am Industry Leader’s Fireside Chat

  • Yaron Pereg Chief Executive Officer, Kahr Medical
  • Nicolas Poirier Chief Scientific Officer, OSE Immunotherapeutics
  • Yang Liu Founder, President and Chief Scientific Officer , Oncoimmune

10:00 am AO-176, a highly differentiated CD47-targeting antibody for the treatment of cancers

10:30 am Using a SIRPα & other new Don’t Eat Me Targeted Myeloid Checkpoint Inhibitor to Develop Safe & Efficacious Treatment for Solid Tumors

11:00 am Development of a macrocyclic peptide that blocks the CD47-SIRPα interaction as a new cancer immunotherapy

11:30 am The Use of In Vitro Macrophage Assays to Accelerate IO Drug Development

  • Thibaut Janss Senior Scientist, ImmunXperts, a Nexelis Group Company

11:45 am Morning Refreshments & Speed Networking

Advancing Development of Next Generation Cancer Immunotherapy by Optimizing Clinical Development of CD47/SIRPα Targeted Macrophage Therapies

12:15 pm DSP107 – A First-In-Class Bi-Functional CD47x41BB Targeting Compound

12:45 pm Targeting Tumor-associated Macrophages using Self-assembled Supramolecule

  • Ashish Kulkarni Assistant Professor of Chemical Engineering , University of Massachusetts Amherst

1:15 pm TTI-621 and TTI-622 target the CD47 “do not eat” signal on tumor cells

  • Gloria Lin Associate Director of Translational Research , Trillium Therapeutics Inc.

Looking Beyond CD47: Exploring Novel Pathways & Proteins to Cement The Future of Macrophage Targeted Therapies

1:45 pm Lunch & Networking

2:45 pm Determining The Potential Of Utilizing CD24 Blockade For Anti-Tumor Treatment

  • Yang Liu Founder, President and Chief Scientific Officer , Oncoimmune

3:15 pm Macrophage Scavenger Receptors as Targets for Anti-Tumor Immunity

  • Juho Jalkanen Chief Development Officer , Faron Pharmaceuticals

3:45 pm Pulmonary Macrophage Transplantation Therapy of Hereditary Pulmonary Alveolar Proteinosis

  • Bruce C. Trapnell Professor of Medicine and Pediatrics, Director, University of Cincinnati College of Medicine, Translational Pulmonary Science Center, Cincinnati Children’s Hospital

4:15 pm Afternoon Refreshments & Poster Session

5:00 pm Audience Discussion: Exploring the Key Questions that Need to be Addressed to Supercharge Macrophage-directed Therapies

Sergio Trombetta

Senior Principal Scientist, Cancer Immunology & Immune Modulation

Boehringer Ingelheim

Ashish Kulkarni

Assistant Professor of Chemical Engineering

University of Massachusetts Amherst

How Do We Characterize
Macrophages for Human Use?

How Do We Determine That Macrophages Are In a Resting State?

How Do You Determine/Define A
Measure Of The State Of Activation Of
Macrophages When It Is Not An
‘All Or Nothing’ Phenomenon?

What Biomarkers Should Be Used To
Indicate That A Macrophage Directed Therapy Is Working?

5:45 pm Chairman’s Closing Remarks

6:00 pm Close of Day 1